Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ondine BiomedicalLSE:OBI +1.85%26 Days Inventory is 422.68 as of Dec. 2025, which is 21% below its 10-year median of 536.92. GuruFocus rates LSE:OBI with a GF Score™ of 26/100 and a GF Value™ of £0.10 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 638 Biotechnology companies, Ondine Biomedical ranks worse than 82.45% on this metric.
The historical rank and industry rank for Ondine Biomedical's Days Inventory or its related term are showing as below:
LSE:OBI'
s Days Inventory Range Over the Past 10 Years
Min: 139.28 Med: 536.92 Max: 1203.81
Current: 523.67
During the past 13 years, Ondine Biomedical's highest Days Inventory was 1203.81. The lowest was 139.28. And the median was 536.92.
LSE:OBI's Days Inventory is ranked worse than 82.45% of 638
companies
in the Biotechnology industry
Industry Median: 183.195
vs LSE:OBI: 523.67
Ondine Biomedical's Days Inventory
declined
from Dec. 2024 (596.63) to Dec. 2025 (422.68).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Ondine Biomedical's Inventory Turnover for the
six
months ended in Dec. 2025 was 0.43.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ondine Biomedical's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.96.
Ondine Biomedical (LSE:OBI) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Ondine Biomedical's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ondine Biomedical's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Ondine Biomedical Days Inventory Related Terms
Ondine Biomedical Days Inventory Historical Data
* Premium members only.
The historical data trend for Ondine Biomedical's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:OBI vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Ondine Biomedical's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ondine Biomedical Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ondine Biomedical's Days Inventory distribution charts can be found below:
* The bar in red indicates where Ondine Biomedical's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ondine Biomedical (LSE:OBI) has a Days Inventory of 422.68 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Ondine Biomedical and its competitors. This is 21% below median its historical median of 536.92. Over the past decade, Ondine Biomedical's Days Inventory has ranged from 139.28 to 1,203.81. According to the industry distribution chart, Ondine Biomedical ranks #526 out of 638 companies in the Biotechnology industry, placing it in the top 82.4%.
Is Ondine Biomedical's Days Inventory too high?
Ondine Biomedical's current Days Inventory of 422.68 is 21% below median its 10-year median of 536.92. Over the past 10 years, this metric has ranged from a low of 139.28 to a high of 1,203.81. The Biotechnology industry median Days Inventory is 183.20. Ondine Biomedical's value of 422.68 is 130.7% above this industry median. Based on the distribution chart, Ondine Biomedical ranks #526 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ondine Biomedical has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ondine Biomedical's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ondine Biomedical ranks #526 out of 638 companies for Days Inventory. This places Ondine Biomedical in the lower half of its industry. The industry median Days Inventory is 183.20. Ondine Biomedical's value of 422.68 is 130.7% above this benchmark. Historically, Ondine Biomedical's own Days Inventory has ranged from 139.28 to 1,203.81 over the past decade. While the company's 10-year median is 536.92 vs. the industry median of 183.20, Ondine Biomedical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ondine Biomedical's current Days Inventory of 422.68 is 130.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Ondine Biomedical and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ondine Biomedical's current Days Inventory is 422.68, which is 21% below median its own 10-year median of 536.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ondine Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Ondine Biomedical (LSE:OBI) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.10, compared to a current price of £0.14 — trading 37.5% above its estimated fair value. The current Days Inventory is 422.68, which is 21% below median its 10-year median of 536.92 and 130.7% above the Biotechnology industry median of 183.20. Ondine Biomedical's overall GF Score™ is 26/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Ondine Biomedical (LSE:OBI), the current Days Inventory is 422.68 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ondine Biomedical (LSE:OBI) Overvalued in 2026?
Based on GuruFocus' analysis, Ondine Biomedical stock appears to be overvalued.
The current stock price of £0.14 is trading 37.5% above its estimated GF Value™ of £0.10.
GuruFocus considers Ondine Biomedical to be Significantly Overvalued.
Key valuation signals for LSE:OBI:
Days Inventory: 422.68 (21% below median its 10-year median of 536.92)
GF Value™: £0.10 vs. price of £0.14 (37.5% above fair value)
Industry Position: 130.7% above the Biotechnology median (#526 of 638)
No single metric tells the full story. See the LSE:OBI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
26GF Score
Get the complete analysis for LSE:OBI
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:OBI has been successfully added to your 
